• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Bepirovirsen may reduce disease burden in patients with chronic hepatitis B

byDavid XiangandKiera Liblik
December 22, 2022
in Chronic Disease, Gastroenterology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Bepirovirsen resulted in a sustained hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA loss in approximately 10% of participants with chronic HBV infection.

2. The bepirovirsen group had significantly increased adverse events compared to the placebo group. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Chronic HBV infection causes approximately 820,000 deaths yearly, with an estimated 1.5 million new infections annually. While therapy aims to achieve a functional cure, with HBsAg loss or sustained undetectable HBV DNA after cessation of therapy, this is uncommon in patients receiving prolonged treatment. In patients receiving prolonged nucleoside or nucleotide analog (NA) therapy (the first-line treatment for HBV), fewer than 5% of patients have HBsAg loss after 12 months of treatment. Bepirovirsen is a 2’-O-methoxy-ethyl modified antisense oligonucleotide, which targets all HBV RNAs, including HBV messenger RNA and pregenomic RNA. However, there is a gap in knowledge as to understanding the efficacy and safety of 12- and 24-week bepirovirsen treatment in participants with chronic HBV infection either receiving stable NA therapy or not receiving NA therapy. Overall, this study found that treatment with bepirovirsen resulted in HBsAg and HBV DNA loss for 24 weeks after the end of treatment. This study was limited by having short follow-up and a small participant pool. Nevertheless, these study’s findings are significant, as they demonstrate that bepirovirsen may be efficacious in treating chronic HBV in inducing a sustained loss of HBsAg and HBV DNA.

Click to read the study in NEJM

Relevant Reading: A Modern Therapy for an Ancient Disease

In-Depth [randomized controlled trial]: This phase two randomized, parallel cohort trial was conducted at 123 sites in 22 countries. Participants 18 years of age or older with documented chronic HBV infection for at least six months and an HBsAg level of more than 100 IU per milliliter were eligible for the study. The primary outcome measured was an HBsAg level below the lower limit of detection and an HBV DNA level below the lower limit of quantification maintained for 24 weeks after the planned end of bepirovirsen treatment. There were four treatment groups: bepirovirsen 300mg for 24 weeks (group 1), bepirovirsen 300mg for 12 weeks then 150mg for 12 weeks (group 2), bepirovirsen 300mg for 12 weeks then placebo for 12 weeks (group 3), and placebo for 12 weeks then bepirovirsen 300mg for 12 weeks (group 4). Based on the primary analysis, among those receiving NA therapy, a primary-outcome event occurred in six participants in group 1 (9%; 95% credible interval, 0 to 31), six in group 2 (9%; 95% credible interval, 0 to 43), two in group 3 (3%; 95% credible interval, 0 to 16), and zero in group 4 (0%; post hoc credible interval, 0 to 8). Among participants not receiving NA therapy, a primary-outcome event occurred in seven (10%; 95% credible interval, 0 to 38), four (6%; 95% credible interval, 0 to 25), one (1%; post hoc credible interval, 0 to 6), and zero participants (0%; post hoc credible interval, 0 to 8), respectively. Adverse events were more common with bepirovirsen (groups 1, 2, and 3) than with placebo (group 4). Overall, this study demonstrates that bepirovirsen at a dose of 300mg per week for 24 weeks resulted in sustained HBsAg and HBV DNA loss in 9-10% of participants with chronic HBV infection.

RELATED REPORTS

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis

Efanesoctocog alfa is efficacious in treating severe hemophilia A

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bepirovirsenchronic diseaseChronic hepatitis BGastroenterologygeneral surgeryHBVhepatitishepatitis bhepatitis b virushepatology
Previous Post

The majority of FDA-approved drug trials recruit from low- and middle-income countries

Next Post

Artificial rupture of membranes alone is effective for induction in women with previous C-section

RelatedReports

Intravenous contrast may not increase risk of acute kidney injury
Chronic Disease

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

February 3, 2023
Physical therapy reduces pain in adults with knee osteoarthritis
Chronic Disease

High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis

February 3, 2023
Nonleg venous thromboses associated with PE, longer ICU stay
Chronic Disease

Efanesoctocog alfa is efficacious in treating severe hemophilia A

February 2, 2023
Few older adolescents meet recommended levels of physical activity
Wellness

Wellness Check: Exercise

February 2, 2023
Next Post
Maternal vaccination during pregnancy not associated with infant hospitalization, mortality

Artificial rupture of membranes alone is effective for induction in women with previous C-section

Bystander and first-responder initiated CPR associated with improved outcomes

Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest – the SAMBA trial

Eczema more prevalent among older adults than previously thought

2 Minute Medicine Rewind December 12, 2022

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options